Asia
Last week there were quite a few clinical trials whose data were presented. Many were at the American Diabetes Association 79th Scientific Sessions, while others were presented at separate meetings or independently. Here’s a look.
Based on the results, which were not disclosed at this time, the company said it will begin to plan for regulatory approval in China.
The collaboration with China-Singapore Guangzhou Knowledge City will focus on the most prevalent cancers in China.
Every week there are numerous scientific studies published. Here’s a look at some of the more interesting ones.
As a sign of its international importance, the BIO Asia-Taiwan 2019 exhibition will feature 18 national pavilions, while the conference will feature speakers from 25 countries
TLC599 showed locally sustained release profile up to 120 days, dose proportionality, minimal systemic exposure and potential for repeat dosing
Singapore Exchange-listed Singapore eDevelopment Limited wishes to announce that its U.S. biomedical subsidiary, Global BioLife Inc., has independently tested a new mosquito repellent formula which performs well against mosquitos for six to eight hours.
Companies from across the globe share business and pipeline updates.
Vygon Asia announces that it has donated 50 Vygon Polysite ISP implantable ports for patients undergoing chemotherapy at the Mount Miriam Cancer Hospital under the One Port One Life program.
The two companies will pair CStone’s CS1001 with Bayer’s regorafenib, an oral multi-kinase inhibitor that targets VEGFR, FGFR, CSF1R and other receptors.
PRESS RELEASES